Spero Therapeutics, Inc. (SPRO)
1.16
-0.02
(-1.69%)
USD |
NASDAQ |
Oct 13, 15:46
Spero Therapeutics Free Cash Flow (Quarterly) : -5.355M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.355M |
| March 31, 2026 | 15.86M |
| December 31, 2025 | -8.351M |
| September 30, 2025 | 17.42M |
| June 30, 2025 | -17.69M |
| March 31, 2025 | -4.002M |
| December 31, 2024 | -23.40M |
| September 30, 2024 | 12.76M |
| June 30, 2024 | -18.74M |
| March 31, 2024 | 5.938M |
| December 31, 2023 | -17.49M |
| September 30, 2023 | 15.92M |
| June 30, 2023 | -18.56M |
| March 31, 2023 | -12.85M |
| December 31, 2022 | 44.48M |
| September 30, 2022 | -0.957M |
| June 30, 2022 | -23.03M |
| March 31, 2022 | -28.22M |
| Date | Value |
|---|---|
| December 31, 2021 | -27.35M |
| September 30, 2021 | -4.952M |
| June 30, 2021 | -16.57M |
| March 31, 2021 | -15.48M |
| December 31, 2020 | -16.40M |
| September 30, 2020 | -21.32M |
| June 30, 2020 | -24.91M |
| March 31, 2020 | -23.41M |
| December 31, 2019 | -17.50M |
| September 30, 2019 | -9.676M |
| June 30, 2019 | -12.16M |
| March 31, 2019 | -11.00M |
| December 31, 2018 | -15.92M |
| September 30, 2018 | -5.514M |
| June 30, 2018 | -8.641M |
| March 31, 2018 | -11.96M |
| December 31, 2017 | -12.77M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -18.05M |
| Fortress Biotech, Inc. | -59.36M |
| Kura Oncology, Inc. | -63.20M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |